Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4041 - Effect of enoxaparin, omeprazole, gemcitabine and bortezomib in refractory patients.


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Translational Research


Juan Marquez-Manriquez


Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390


J.P. Marquez-Manriquez

Author affiliations

  • Clinic Of Refractory Tumors And Relapse Prevention, Centro de Investigacion de Cancer en Sonora campus Seattle, 98036 - Seattle/US


Abstract 4041


Repurposing drugs and immunogenic chemotherapy for cancer is an emerging field, especially the combination of drugs with validated data. Several studies have shown that enoxaparin, omeprazole, gemcitabine and bortezomib have immunomodulatory properties that synergize with several chemotherapeutic protocols and decrease chemoresistance in several tumors. We treated refractory patients with ECOG=0 with this combination. We demonstrated significant clinical response that correlated with the immune response after 2 months of weekly treatment.


CICS IRB approved this protocol and inform of consent was signed. We included 10 patients, median age 45 years old of each tumor with at least 2-4 relapses. The patients receive intravenous 0.5 gr/m2 of gemcitabine, 3.5 mg of bortezomib, 80 mg of omeprazole and enoxaparin was administrated subcutaneously in the area with more tumor activity according with the CT SCAN, Granzyme B ELISPOT and cytokine ELISA that were performed before, during and after the treatment. We analyzed the data with prism graph pad and by multivariate analysis using SAS/STAT.


We had a significant correlation between increased levels of CD8 cells (p = 0.0003) and PFS in the 100% of the patients. The cytokines measured were downregulated after the treatment with significant correlation with IL-6 (p = 0.001), IL-8 (p = 0.001), IL-18, (p = 0.01) and TNF alpha (p = 0.005) and CR after the third CT scans. The laboratory tests before, during and after the treatment did not demonstrate clinical significant toxicity.


The results obtained in this pilot study gave relevant data to prepare a phase I trial. We conclude that this combination is feasible to overcome chemoresistance and improve the anti-tumor immune response by CD8 cells and decreasing cytokines associated with tumor progression.

Clinical trial identification

Does not apply

Legal entity responsible for the study

Centro de Investigacion de cancer en Sonora (CICS) campus Ciudad Obregon, Sonora, Mexico.


Fundacion del Centro de Investigacion de cancer en Sonora campus Ciudad Obregon


The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.